Non-Industrial Robots Market is Expand at a CAGR of 18.8% During Forecast Period – By Fact.MR

Robotics is gradually changing how routine tasks are carried out; their adoption simplifies work, saves time, and increases overall productivity.

Every industry, including the commercial and domestic sectors, uses robots for all jobs, simple or complex. Due to the growing demand from end-use sectors like healthcare, the military, research and development, and other industries, non-industrial robots are expected to experience rapid growth.

“Demand across Defense Sector to Supplement Non-Industrial Robots Sales”

Robots with the advancing technology, witness high adoption across various end-use verticals over the period. The defense sector creates high growth opportunities for non-industrial robots as they ease out difficult military tasks.

For instance, the use of robots to spy, deliver goods and services, rescue operations, robot dogs for search missions, and others. Such factors augment the sales of non-industrial robots.

Further, the use of sensors, autonomy, navigation/control systems, and energy/propulsion systems, among others, assists military personnel to accomplish the mission efficiently. Owing to such factor military is spending highly on non-industrial robots.

Competitive Analysis

Prominent non-industrial robots Diligent Robotics, ReWalk Robotics, Barrett Advanced Robotics, Stryker, Hanson Robotics, Pal Robotics, UBTECH Robotics, Macco Robotics, Intuitive Robots, Samsung Electronics, and Skydio Robots, among others.

Market titans are experiencing high demand for non-industrial robots due to their adoption across various end-use verticals. Manufacturers are also integrating robots with advanced technology to enhance their performance and cater to the needs of the end-users. In addition, long-term trade relations with end-users enable market players to survive in unfavourable trade situations.

Fact.MR has provided detailed information about the price points of key manufacturers of non-industrial robots positioned across regions, sales growth, production capacity, and speculative technological expansion, in the recently published report.

 

These insights are based on a report on Non-Industrial Robots Market by Fact.MR. 

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version